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Abstract
Introduction: The purpose of this study was to investigate the effectiveness of adalimumab in enthesitis and
peripheral arthritis in patients with ankylosing spondylitis (AS).
Methods: Adults with active AS (Bath ankylosing spondylitis disease activity index [BASDAI] ≥ 4) received
adalimumab 40 mg every other week with standard antirheumatic therapies in a 12-week, open-label study.
Effectiveness in enthesitis was assessed using the Maastricht ankylosing spondylitis enthesitis score (MASES, 0-13)
and by examining the plantar fascia in patients with enthesitis (≥ 1 inflamed enthesis) at baseline; effectiveness in
peripheral arthritis was evaluated using tender and swollen joint counts (TJC, 0-46; SJC, 0-44) in patients with
peripheral arthritis (≥ 1 swollen joint) at baseline. Overall effectiveness measures included Assessment of
SpondyloArthritis International Society 20% response (ASAS20).
Results: Of 1,250 patients enrolled, 686 had enthesitis and 281 had peripheral arthritis. In 667 patients with MASES
≥ 1 at baseline, the median MASES was reduced from 5 at baseline to 1 at week 12. At week 12, inflammation of
the plantar fascia ceased in 122 of 173 patients with inflammation at baseline. The median TJC in 281 patients with
SJC ≥ 1 at baseline was reduced from 5 at baseline to 1 at week 12; the median SJC improved from 2 to 0.
ASAS20 responses were achieved by 70.5% of 457 patients with no enthesitis and no arthritis; 71.0% of 512
patients with only enthesitis; 68.0% of 107 patients with only arthritis; and 66.7% of 174 patients with both.
Conclusions: Treatment with adalimumab improved enthesitis and peripheral arthritis in patients with active AS.
Trial registration: ClinicalTrials.gov NCT00478660.
Introduction
In addition to chronic inflammation of the spine, extra-
axial manifestations are common features in patients
with ankylosing spondylitis (AS). Enthesitis and periph-
eral arthritis, predominantly of the lower limbs, occur in
up to 50% of patients with AS during the course of the
disease [1-5]. These extra-axial manifestations of AS
contribute to the burden of the disease [6,7].
Nonsteroidal anti-inflammatory drugs (NSAIDs)
remain first-line agents for the treatment of AS and can
be used for the treatment of enthesitis [8]. Disease-mod-
ifying antirheumatic drugs (DMARDs) do not have a
satisfactory effect on axial disease. Sulfasalazine has
some effect on extra-axial arthritis [9] but its benefit for
treating enthesitis does not outweigh its risks [8].
Tumor necrosis factor (TNF) antagonists, including the
monoclonal antibodies adalimumab and infliximab and
the TNF-receptor construct etanercept, are highly effec-
tive agents for the treatment of patients who have active
AS despite NSAID treatment [9-18].
In a 24-week, randomized, double-blind, placebo-con-
trolled study of patients with active AS, 152 adalimu-
mab-treated patients experienced a significant reduction
in enthesitis compared with 81 placebo-treated patients
but no significant improvement in peripheral arthritis
[15]. Similarly, other randomized controlled trials
(RCTs) of TNF antagonists have not consistently
demonstrated significant improvements in both enthesi-
tis and peripheral arthritis for TNF-antagonist-treated
* Correspondence: publications@jkmed.com
1Charité-University Medicine Berlin, Benjamin Franklin Campus, Medical
Department I, Rheumatology, Hindenburgdamm 30, 12203 Berlin, Germany
Rudwaleit et al. Arthritis Research & Therapy 2010, 12:R43
http://arthritis-research.com/content/12/2/R43
© 2010 Rudwaleit et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.patients compared with placebo-treated patients
[10,12,14,16,17]. Only in one RCT of infliximab in AS
were significant improvements in both tender joint
c o u n t( T J C )a n ds w o l l e nj o i n tc o u n t( S J C )o b s e r v e d
[10]. We evaluated the effects of adalimumab on enthe-
sitis and peripheral arthritis in a large cohort of 1,250
patients with active AS who were enrolled in the open-
label RHAPSODY (Review of Safety and Effectiveness
with Adalimumab in Patients with Active Ankylosing
Spondylitis) study [1].
Materials and methods
The patient sample and methods of the RHAPSODY
study, an open-label, multicenter study conducted at
211 centers in 15 European countries, were previously
described in detail [1]. Independent ethics committees
at all participating centers approved the study, and all
participating patients gave written informed consent.
Patients
Patients who were at least 18 years old and who had AS
according to the modified 1984 New York Criteria for
AS [19] and active disease defined by a Bath Ankylosing
Spondylitis Disease Activity Index (BASDAI) score of at
least 4 [20] were eligible for this study if at least one
NSAID or (if stipulated by national guidelines) at least
two NSAIDs had failed to control their disease. Patients
were permitted to continue current AS therapy with
NSAIDs, DMARDs, analgesics, and glucocorticoids (≤
10 mg/d of prednisone equivalent) during the study.
Intra-articular injections or infiltrations of extra-axial
joints and tendons were not permitted within 28 days
and injections of sacroiliac joints were not permitted
within 14 days before screening or during the study.
Previous anti-TNF therapy was permitted provided that
etanercept had been discontinued at least 3 weeks or
infliximab had been discon t i n u e da tl e a s t2m o n t h s
before the first adalimumab injection.
Study design
At baseline, clinicians documented the presence or
absence of enthesitis and peripheral arthritis. Enthesitis
was defined as at least 1 inflamed enthesis in the Maas-
tricht Ankylosing SpondylitisE n t h e s i t i sS c o r e( M A S E S )
(0 to 13) [21] or of the plantar fascia of the foot. Periph-
eral arthritis was defined as an SJC of at least 1 (0 to 44,
excluding hip joints).
Patients self-administered 40 mg of adalimumab
(Abbott Laboratories, Abbott Park, IL, USA) subcuta-
neously every other week for 12 weeks. The treatment
effect of adalimumab for enthesitis was assessed by mea-
s u r i n gt h ec h a n g ef r o mb a s e l i n et ow e e k1 2i nt h e
MASES (for patients with MASES of at least 1 at
baseline) and the change from baseline to week 12 in
the percentage of patients with enthesitis of the plantar
fascia (for patients with inflammation of the plantar fas-
cia at baseline). The treatment effect of adalimumab for
peripheral arthritis was assessed by measuring the
change in TJCs (0 to 46) and SJCs from baseline to
weeks 2, 6, and 12. Overall adalimumab effectiveness
was measured using the Assessment of SpondyloArthri-
tis International Society 20% and 40% responses
(ASAS20 and ASAS40, respectively) [20,22] and using a
50% improvement in the BASDAI (BASDAI 50) [23,24].
In addition, absolute values at each study visit (weeks 2,
6, and 12, as applicable) and changes from baseline were
calculated for BASDAI (0 to 10) [20], Bath Ankylosing
Spondylitis Functional Index (BASFI) (0 to 10) [25], the
Patient’s Global Assessment of disease activity (PaGA)
(based on a visual analog scale of 0 to 100 mm), and
C-reactive protein (CRP) serum concentration.
Statistical analysis
Patients who had received at least one injection of adali-
mumab were included in the analyses. Observed data
were used for all effectiveness analyses, and week 12
was specified as the endpoint. Patients with MASES of
at least 1 and patients with SJC of at least 1 were strati-
fied by sex (male or female), HLA-B27 positivity (posi-
tive or negative), and concomitant DMARD therapy (yes
or no) to analyze changes in MASES, TJC, and SJC. The
effects of adalimumab on AS disease activity and func-
tional disability were evaluated in four subgroups: (a)
patients with no enthesitis and no peripheral arthritis,
(b) patients with enthesitis and no peripheral arthritis,
(c) patients with peripheral arthritis and no enthesitis,
and (d) patients with both enthesitis and peripheral
arthritis.
Descriptive analyses were performed by calculating
counts and percentages for qualitative data and by cal-
culating medians and first and third quartiles for quan-
titative data. For the three patient groups without
arthritis and enthesitis, with either peripheral arthritis
or enthesitis, and with both, the Jonckheere-Terpstra
test was applied to test for trends in baseline values and
absolute changes from baseline to week 12 in BASDAI,
BASFI, PaGA, and CRP. For the median absolute
change from baseline to week 12 in MASES, TJC, SJC,
BASDAI, BASFI, PaGA, and CRP, nonparametric 95%
confidence intervals (CIs) were calculated. Correlations
between improvements in AS overall (measured by
changes in BASDAI and in BASFI) and improvements
in extra-axial manifestations (measured by changes in
MASES, plantar fascia, TJC, and SJC) at week 12 were
assessed using the Spearman rank order correlation
coefficient.
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Patient disposition
A total of 1,250 patients with AS were enrolled. Through
week 12, 7.3% of the patients discontinued adalimumab
therapy [1]. Of enrolled patients, 457 (36.6%) patients
had no enthesitis and no peripheral arthritis at baseline
(Figure 1). Enthesitis (MASES or plantar fascia or both of
at least 1) was reported in 686 (54.9%) patients. At least
one inflamed enthesis in MASES was documented for
667 patients, and inflammation of the plantar fascia was
reported for 173 patients, including 19 patients without
enthesitis in MASES. The distribution of enthesitis sites
at baseline is shown in Figure 2. Of the 281 (22.5%)
patients with peripheral arthritis (SJC of at least 1) at
baseline, 96 had tenderness of the hip joint, indicating
possible hip involvement. Enthesitis without peripheral
arthritis was documented in 512 (41.0%) patients; arthri-
tis without enthesitis was reported in 107 (8.6%) patients.
Both enthesitis and peripheral arthritis were present in
174 of 1,250 (13.9%) patients.
Baseline characteristics
Patients with enthesitis or peripheral arthritis or both
The mean age of patients and the mean duration of AS
were similar between patient subgroups, irrespective of
the presence of enthesitis and arthritis (Table 1). The
percentage of men was lower in the patient subgroups
with enthesitis or peripheral arthritis or both (range,
58.0% to 69.2%) than in the subgroup with no enthesitis
and no arthritis (80.7%). The percentage of patients with
HLA-B27 was lower in the subgroup with both enthesi-
tis and peripheral arthritis (76.0%) than in the other
subgroups (range, 82.2% to 84.1%). The patient sub-
group with peripheral arthritis and no enthesitis had the
greatest percentages of patients receiving concomitant
therapy with DMARDs (45.8%) or glucocorticoids
(29.9%). Median BASDAI,B A S F I ,a n dP a G As c o r e s
were lower in patients with no enthesitis and no arthri-
tis than in patients with enthesitis or peripheral arthritis
or both (P < 0.005) (Table 2).
Patients with MASES of at least 1 at baseline
The median MASES was 5 for the 667 patients with
MASES of at least 1 at baseline (Table 3). The median
MASESs were 4 for 432 male patients and 7 for 236
female patients, 5 for both 523 HLA-B27-positive
patients and 126 HLA-B27-negative patients, and 5 for
499 patients without concomitant DMARD treatment at
baseline and 4 for 168 patients with concomitant
DMARD therapy at baseline.
Patients with enthesitis of plantar fascia
The percentages of patients with enthesitis of the plan-
tar fascia were 11.8% in men (105 of 891 men) and
18.9% in women (68 of 359 women).
Patients with a swollen joint count of at least 1 at baseline
The median TJCs and SJCs were 5 and 2, respectively,
at baseline for 281 patients with an SJC of at least 1
Patients with AS enrolled in RHAPSODY (N = 1,250)
(211 sites in 15 European countries)
Patients with 
no enthesitis 
+ no peripheral arthritis
(n = 457) 
Patients with 
enthesitis 
(n = 686)*
Patients with 
peripheral arthritis 
(n = 281)
Patients with
enthesitis 
+ peripheral arthritis
(n = 174)
Patients with
peripheral arthritis
+ no enthesitis 
(n = 107)
Patients with 
enthesitis 
+ no peripheral arthritis
(n = 512)
Figure 1 Distribution of enthesitis or peripheral arthritis or both in patients with ankylosing spondylitis (AS) (n = 1,250). Enthesitis is
defined as at least 1 inflamed enthesis in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) or plantar fascia, and peripheral arthritis is
defined as at least 1 swollen joint in a 44-joint count. Data are observed values. *Six hundred sixty-seven patients with enthesitis in MASES and
173 patients with enthesitis of fascia plantaris (19 patients had enthesitis of fascia plantaris without enthesitis in MASES). RHAPSODY, Review of
Safety and Effectiveness with Adalimumab in Patients with Active Ankylosing Spondylitis.
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Figure 2 Percentages of patients with inflamed entheses at baseline and week 12 by enthesitis site (n = 686). Enthesitis is defined as at
least 1 inflamed enthesis in Maastricht Ankylosing Spondylitis Enthesitis Score or plantar fascia and includes patients with ankylosing spondylitis
and enthesitis. Data are observed values.
Table 1 Baseline characteristics in patients with ankylosing spondylitis by subgroup of enthesitis or peripheral
arthritis or both
Patient subgroups
Characteristic No enthesitis
+ no arthritis (n = 457)
Enthesitis
+ no arthritis (n = 512)
Arthritis
+ no enthesitis (n = 107)
Enthesitis
+ arthritis
(n = 174)
Age, years 43.1 ± 11.2 42.7 ± 11.1 46.0 ± 11.9 46.1 ± 12.3
Males, percentage 80.7 67.8 69.2 58.0
HLA-B27-positive, percentage 83.7 82.2 84.1 76.0
AS duration, years 10.9 ± 9.4 10.5 ± 9.7 12.3 ± 10.6 11.8 ± 10.5
Advanced AS, percentage 25.2 28.4 27.6 26.5
Concomitant NSAIDs, percentage 74.0 76.8 73.8 68.4
Concomitant DMARDs, percentage 21.7 22.1 45.8 35.6
Concomitant glucocorticoids
a, percentage 10.1 10.9 29.9 20.1
Prior TNF-antagonist therapy, percentage 25.8 25.0 27.1 29.3
Data are mean ± standard deviation unless otherwise noted.
aSystemic treatment with not more than 10 mg of prednisone equivalent daily. AS, ankylosing
spondylitis; DMARD, disease-modifying antirheumatic drug; NSAID, nonsteroidal anti-inflammatory drug; TNF, tumor necrosis factor.
Rudwaleit et al. Arthritis Research & Therapy 2010, 12:R43
http://arthritis-research.com/content/12/2/R43
Page 4 of 10(Table 3). Knees (35% of joints), ankles (35%), and hips
(30%) were most frequently affected by tenderness,
whereas of the joints of the upper limbs, the greatest
percentages of joint tenderness were observed in the
wrists (28%) and shoulders (27%). Similarly, of the joints
of the lower limbs, the greatest percentages of joint
swelling were reported for knees (25%) and ankles (22%)
compared with 19% for the wrists. (The hips were not
evaluated for swelling.) For fingers and toes, swelling
was more frequently reported for the metacarpophalan-
geal joints and proximal interphalangeal joints (4% to
17%) than for the metatarsophalangeal (MTP) joints (1%
to 6%), probably because swelling in the MTP joints is
difficult to evaluate. The median TJCs were 4 for 175
male patients and 7 for 106 female patients, 5 for 217
HLA-B27-positive patients and 6 for 57 HLA-B27-nega-
tive patients, and 4 for 170 patients not receiving conco-
mitant DMARD therapy and 6 for 111 receiving
concomitant DMARD therapy. The median SJC was 2,
regardless of sex, HLA-B27, and DMARD treatment.
Adalimumab effectiveness at week 12
Enthesitis
For patients with MASES of at least 1 at baseline, the
median MASES decreased from 5 at baseline to 1 at
week 12; the median change in MASES from baseline to
week 12 was -2 (Table 3). The median MASESs at week
12 were 1 for women (median reduction, -3) and 0 for
men (median reduction, -2). The improvement in
MASES was independent of HLA-B27 positivity and
Table 2 Effectiveness of adalimumab at week 12 in patients with ankylosing spondylitis by subgroup of enthesitis or
peripheral arthritis or both
No enthesitis
+ no arthritis
(n = 457)
Enthesitis
+ no arthritis
(n = 512)
Arthritis
+ no enthesitis
(n = 107)
Enthesitis
+ arthritis
(n = 174)
P value
a
Median First quartile, third quartile [95% confidence interval]
BASDAI, 0 to 10
Baseline 5.9
4.9, 6.9
6.4
5.4, 7.5
6.7
5.7, 7.7
6.6
5.7, 7.6
< 0.001
Week 12 2.1
0.8, 4.1
2.6
1.1, 5.1
3.1
1.5, 4.8
2.7
1.2, 5.0
Change from baseline to week12 -3.6
-4.8, -1.7
[-3.8 to -3.3]
-3.4
-4.9, -1.5
[-3.7 to -3.1]
-3.1
-5.0, -1.8
[-4.0 to -2.7]
-3.5
-4.9, -1.7
[-3.7 to -2.9]
0.813
BASFI, 0 to 10
Baseline 4.9
3.4, 6.7
5.7
4.0, 7.3
5.8
3.7, 7.0
6.0
4.3, 7.5
< 0.001
Week 12 2.2
1.0, 4.3
2.7
1.0, 5.1
3.1
1.4, 5.3
2.8
1.3, 5.3
Change from baseline to week12 -1.9
-3.6, -0.7
[-2.1 to -1.7]
-2.1
-3.8, -0.6
[-2.4 to -1.7]
-1.8
-3.2, -0.7
[-2.2 to -1.5]
-1.9
-3.7, -0.5
[-2.2 to -1.5]
0.828
Patient’s Global Assessment of disease activity, 0- to 100-mm visual analog scale
Baseline 67
49, 80
71
53, 83
72
54, 81
72
53, 83
0.004
Week 12 21
8, 46
24
8, 52
25
11, 48
26
10, 52
Change from baseline to week12 -35
-58, -14
[-40 to -32]
-38
-59, -15
[-42 to -34]
-39
-61, -13
[-48 to -26]
-33
-57, -12
[-41 to -24]
0.806
C-reactive protein
b, mg/dL
Baseline 1.2
0.6, 2.5
1.2
0.5, 2.4
1.5
0.8,3.6
1.3
0.6, 3.4
0.448
Week 12 0.4
0.2, 0.8
0.4
0.2, 0.8
0.6
0.2, 1.5
0.4
0.1, 0.9
Change from baseline to week12 -0.7
-2.1, -0.1
[-0.9 to -0.6]
-0.8
-1.7, -0.2
[-1.0 to -0.7]
-1.4
-1.7, -0.1
[-1.0 to -0.4]
-0.7
-2.6, -0.1
[-1.3 to -0.4]
0.857
aP values (two-sided) are based on Jonckheere-Terpstra tests for trends between subgroups without enthesitis and peripheral arthritis, with either enthesitis or
peripheral arthritis, and with both.
bReference value is 0.4 mg/dL. BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis
Functional Index.
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fascia resolved in 122 of 173 (70.5%) patients (77 men
and 45 women) at week 12. Overall, similar improve-
ments in enthesitis were observed across enthesitis sites
(Figure 2).
Peripheral arthritis
After 12 weeks of treatment with adalimumab, the TJC
for 281 patients with peripheral arthritis (SJC of at least
1) decreased from a median of 5 at baseline to 1, with a
median reduction of -3 (Table 3). The SJC improved
from a median of 2 at baseline to 0 at week 12, with a
median reduction of -1. Rapid improvement in periph-
eral arthritis was observed, with reductions in the med-
ian TJC and SJC documented after a single injection of
adalimumab; at week 2, the median TJC was 2 and the
median SJC was 0.
Overall
As shown in Figure 3, the percentage of patients achiev-
ing ASAS20 response at week 12 was lowest in the
subgroup of patients with both enthesitis and peripheral
arthritis (66.7%) at baseline compared with the other
patient subgroups (68.0 to 71.0%), whereas the percen-
tage achieving ASAS40 response was lower in the
subgroup with peripheral arthritis and no enthesitis
(46.0%) compared with the others (50.6% to 56%). Simi-
larly, the percentage achieving a BASDAI50
response was lower in patients with peripheral arthritis
and no enthesitis (52.9%) than in other subgroups
(54.9% to 61.5%). Median changes from baseline to
week 12 and 95% CIs in BASDAI, BASFI, PaGA, and
CRP were similar between patient subgroups (P >0 . 8 )
(Table 2).
Table 3 MASES, tender joint count, and swollen joint count by sex, HLA-B27 positivity, and concomitant DMARD use
All Male Female HLA-B27-
negative
HLA-B27-
positive
No concomitant DMARD at
baseline
Concomitant DMARD at
baseline
Median
First quartile, third quartile
[95% confidence interval]
Patients with enthesitis, MASES ≥ 1 at baseline
MASES: 0 to 13, number
(percentage)
667
(100)
431
(64.6)
236
(35.4)
126
(18.9)
a
523
(78.4)
a
499
(74.8)
168
(25.2)
Baseline 5
2, 8
4
2, 7
7
4, 9
5
2, 9
5
2, 8
5
2, 8
4
2, 8
Week 12 1
0, 4
0
0, 2
1
0, 5
1
0, 5
0
0, 3
0
0, 3
1
0, 4
Change from baseline to
week 12
-2
-5,-1
[-3 to
-2]
-2
-5,-1
[-3 to
-2]
-3
-6,-1
[-4 to
-2]
-2
-5,-1
[-3 to -2]
-3
-6,-1
[-3 to -2]
-3
-5,-1
[-3 to -2]
-2
-5,-1
[-5 to -2]
Patients with peripheral arthritis, SJC ≥ 1 at baseline
TJC: 0 to 46, number
(percentage)
281
(100)
175
(62.2)
106
(37.7)
57
(20.3)
a
217
(77.2)
a
170
(60.5)
111
(39.5)
Baseline 5
2, 12
4
2, 10
7
3, 14
6
3, 13
5
2, 12
4
2, 10
6
3, 13
Week 12 1
0, 3
1
0, 3
1
0, 4
1
0, 4
0
0, 3
0
0, 3
1
0, 4
Change from baseline to
week 12
-3
-8,-1
[-4 to
-2]
-2
-6,-1
[-3 to
-2]
-4
-10,-2
[-6 to
-3]
-3
-10,-1
[-6 to -2]
-3
-7,-1
[-4 to -2]
-2
-7,-1
[-3 to -2]
-3
-9,-2
[-4 to -2]
SJC: 0 to 44, number
(percentage)
281
(100)
175
(62.2)
106
(37.7)
57
(20.3)
a
217
(77.2)
a
170
(60.5)
111
(39.5)
Baseline 2
1, 4
2
1, 3
2
1, 6
2
1, 6
2
1, 4
2
1, 3
2
1, 6
Week 12 0
0, 1
0
0, 1
0
0, 1
0
0, 1
0
0, 1
0
0, 1
0
0, 1
Change from baseline to
week 12
-1
-3,-1
[-2 to
-1]
-1
-3,-1
[-2 to
-1]
-2
-4,-1
[-2 to
-1]
-1
-4,-1
[-2 to -1]
-1
-3,-1
[-2 to -1]
-1
-2,-1
[-1 to -1]
-2
-4,-1
[-2 to -2]
aBecause of missing data, the percentages of patients with HLA-B27 status do not sum to 100%. DMARD, disease-modifying antirheumatic drug; MASES,
Maastricht Ankylosing Spondylitis Enthesitis Score; SJC, swollen joint count; TJC, tender joint count.
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improvements in enthesitis or peripheral arthritis or both
Improvement in AS disease activity and functional sta-
tus, measured by BASDAI and BASFI, respectively, did
not correlate with improvement in enthesitis, measured
by MASES and inflammation of the plantar fascia, or
improvement in peripheral arthritis, measured by TJC
and by SJC. Spearman rank order correlation coeffi-
cients ranged from 0.03 to 0.24 across evaluations of the
various combinations of measures.
Discussion
Adalimumab effectiveness and safety were investigated
in a large cohort of patients with AS in an open-label,
uncontrolled, multinational study designed to reflect
r o u t i n er h e u m a t o l o g yp r a c t i c e[ 1 ] .T h ep a t i e n t sh a d
long-standing, active AS with a broad range of disease
manifestations typically associated with AS and were
considered eligible for TNF-antagonist therapy [9].
Herein, we specifically assessed the effectiveness of ada-
limumab in AS patients with or without enthesitis or
peripheral arthritis. The baseline frequency of current
enthesitis (54.9%) in this population and that reported
in a previous adalimumab RCT (74%) [15] are both
markedly greater than the frequency reported in recent
national observational studies (15% to 30%) [1-3],
whereas the rate of current peripheral arthritis found in
this study was in accordance with rates reported in the
literature [2].
In this study, adalimumab therapy was associated with
substantial improvement in enthesitis from baseline to
week 12, as indicated by changes in MASES, and in
inflammation across all examined entheses, including
the plantar fascia. Our results are consistent with results
of a previous RCT of adalimumab in 315 patients with
AS [15] and with an RCT of infliximab [14], although
comparison with the latter trial is limited by the use of
disparate enthesitis scores.
In the present study, peripheral arthritis in the 281
patients who had at least 1 swollen joint at baseline
improved rapidly and substantially during adalimumab
therapy, with half of the patients reporting no swollen
joints at week 12 (week-12 median TJC = 1 and SJC = 0).
Because of the skewed distribution of values, median data
are presented here. In a previous adalimumab RCT in
which mean data were published [15], the mean change
at week 12 in TJC was -0.8 and the mean change in SJC
was -0.4. By comparison, in our study, the mean changes
from baseline to week 12 were -4.9 for TJC and -2.9 for
SJC, and the median changes were lower than these
mean changes (TJC, -3 and SJC, -1). Significant decreases
in TJC and SJC from baseline to week 12 have been
reported for infliximab therapy for AS [10].
Women with AS had a greater number of inflamed
joints and inflamed entheses at baseline than men.
A l t h o u g ht h ep r e s e n c eo fc o e x i s t i n gf i b r o m y a l g i ai n
some of the female patients cannot be excluded, the pat-
tern of enthesitis localization as measured by MASES
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Page 7 of 10and examination of the plantar fascia is typical for
enthesitis in AS (Figure 2) [21,26]. Moreover, the finding
that female patients improved as much as male patients
after 12 weeks of adalimumab therapy suggests that
coexisting fibromyalgia did not contribute substantially
to the greater enthesitis count at baseline in women.
The frequency of and improvement in enthesitis and
peripheral arthritis appeared to be unaffected by HLA-
B27 status and concomitant DMARD therapy.
The burden of disease at baseline, as measured by
BASDAI, BASFI, and PaGA, was lower for patients with
no enthesitis and no peripheral arthritis than for
patients with either one or both of these manifestations
(P < 0.005). These results are in accordance with pre-
vious literature reports [7,27,28]. Of note, two studies
showed that a greater BASDAI in patients with periph-
eral arthritis was not associated with the joint-specific
BASDAI items [27,29]. Although disease activity and
physical impairment differed notably at baseline, the
magnitude of improvement with adalimumab therapy in
patients with enthesitis or peripheral arthritis or both
was similar to that observed for patients without these
extra-axial manifestations. At week 12, the median
changes in BASDAI, BASFI, PaGA, and CRP were simi-
lar between all of the various subgroups, and no impor-
tant differences in the degree of improvement were
detected. However, slightly greater ASAS40 and BAS-
DAI 50 response rates were observed for patients with
no enthesitis and no arthritis than for those with enthe-
sitis or arthritis or both. The results of this study of
patients with AS categorized by enthesitis and arthritis
are consistent with previous predictor analyses, which
found that enthesitis and arthritis did not influence the
effect of TNF-antagonist therapy [1].
We did not detect any correlation between improve-
ment in BASDAI and BASFI with improvement in
enthesitis or peripheral arthritis. In comparison with
joint counts and enthesitis counts, which capture a sin-
gle domain of AS that may entirely resolve, BASDAI
and BASFI capture many disease domains of AS, each
of which may respond differently to therapy.
Conclusions
In this large cohort of patients with active AS, adalimu-
mab treatment effectively reduced enthesitis and periph-
eral arthritis. Although the burden of disease is greater
when AS is associated with enthesitis or peripheral
arthritis or both, patients with these extra-axial manifes-
tations benefited from adalimumab treatment as much
as patients with axial disease only.
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